Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2′-furyl)-1,2,4-triazolo[1,5-a]quinoxalines

被引：17

作者：

Martinez, Ana ^{[1
]}

Gutierrez-de-Teran, Hugo ^{[2
]}

Brea, Jose ^{[2
]}

Ravina, Enrique ^{[1
]}

Loza, Maria Isabel ^{[2
]}

Cadavid, Maria Isabel ^{[2
]}

Sanz, Ferran ^{[3
]}

Vidal, Bernat ^{[4
]}

Segarra, Victor ^{[4
]}

Sotelo, Eddy ^{[1
]}

机构：

[1] Univ Santiago de Compostela, Fac Pharm, Dept Organ Chem, E-15782 Santiago De Compostela, Spain

[2] Univ Santiago de Compostela, Fac Pharm, Dept Pharmacol, E-15782 Santiago De Compostela, Spain

[3] Univ Pompeu Fabra, Dep CEXS, IMIM, Unitat Recerca Informat Med GRIB, E-08003 Barcelona, Spain

[4] Almirall, Dept Med Chem, E-08960 Barcelona, Spain

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2008年 / 16卷 / 04期

关键词：

adenosine receptor binding; 1,2,4-Triazolo[1.5-alpha] quinoxalines;

D O I：

10.1016/j.bmc.2007.10.103

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A collection of 25 2-(2'-furyl)-1,2,4-triazolo[1,5-a]quinoxalines incorporating different substitution patterns at position 4 have been synthesized and their binding affinity towards human adenosine receptors (hA1, hA(2A), hA(2B) and hA(3)) was determinated. The biological data show that several potent at hA1, but lightly selective, adenosine ligands were identified. Moreover, these results confirmed the hypothesis that the structural modi. cations carried out on the 4-position of the tricyclic system produces a remarkable modi. cation of the adenosine receptorial pro. le. A 3D-QSAR modelling study (GRIND/ALMOND methodology) performed on the hA(1) data gave further support to the pharmacological results, and it is presented as a useful tool for the future design of ligands with better pharmacological profiles. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：2103 / 2113

页数：11

共 60 条

[1] Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors
Afzelius, L
Masimirembwa, CM
Karlén, A
Andersson, TB
Zamora, I
[J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2002, 16 (07) : 443 - 458
[2] [Anonymous], 1988, Journal of chemometrics
[3] Baraldi PG, 2000, MED RES REV, V20, P103, DOI 10.1002/(SICI)1098-1128(200003)20:2<103::AID-MED1>3.0.CO
[4] 2-X
[5] Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists
Baraldi, PG
Tabrizi, MA
Preti, D
Bovero, A
Romagnoli, R
Fruttarolo, F
Zaid, NA
Moorman, AR
Varani, K
Gessi, S
Merighi, S
Borea, PA
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) : 1434 - 1447
[6] New strategies for the synthesis of A3 adenosine receptor antagonists
Baraldi, PG
Bovero, A
Fruttarolo, F
Romagnoli, R
Tabrizi, MA
Preti, D
Varani, K
Borea, PA
Moorman, AR
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (19) : 4161 - 4169
[7] New potent and selective human adenosine A3 receptor antagonists
Baraldi, PG
Borea, PA
[J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (12) : 456 - 459
[8] A1 and A3 adenosine receptor agonists:: an overview
Baraldi, PG
Cacciari, B
Romagnoli, R
Spalluto, G
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (05) : 515 - 527
[9] 1,2,3-triazolo[1,5-a]quinoxalines: synthesis and binding to benzodiazepine and adenosine receptors
Bertelli, L
Biagi, G
Giorgi, I
Manera, C
Livi, O
Scartoni, V
Betti, L
Giannaccini, G
Trincavelli, L
Barili, PL
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1998, 33 (02) : 113 - 122
[10] New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist n-ethylcarboxamidoadenosine
Beukers, MW
Chang, LCW
Künzel, JKVD
Mulder-Krieger, T
Spanjersberg, RF
Brussee, J
Ijzerman, AP
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (15) : 3707 - 3709

← 1 2 3 4 5 6 →